Ditchcarbon
  • Contact
  1. Organizations
  2. Medigene AG
Public Profile
Pharmaceutical Preparation Manufacturing
DE
updated 15 days ago

Medigene AG Sustainability Profile

Company website

Medigene AG, a pioneering biotechnology company headquartered in Germany, focuses on the development of innovative immunotherapies for cancer treatment. Founded in 1997, Medigene has established itself as a leader in the field, particularly in the areas of T cell immunotherapy and personalised medicine. With a strong operational presence in Europe and North America, the company is renowned for its unique core products, including its proprietary T cell receptor (TCR) technology, which enables the targeting of specific cancer cells. Medigene's commitment to advancing cancer therapies has led to significant milestones, including successful clinical trials and strategic partnerships that enhance its market position. As a result, Medigene AG continues to be at the forefront of the biopharmaceutical industry, driving innovation in cancer treatment.

DitchCarbon Score

How does Medigene AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

24

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

30

Industry Benchmark

Medigene AG's score of 24 is lower than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.

38%

Let us know if this data was useful to you

Medigene AG's reported carbon emissions

In 2023, Medigene AG reported total carbon emissions of approximately 458,590 kg CO2e, a decrease from about 492,850 kg CO2e in 2022. The emissions are categorised entirely under Scope 1, with no reported emissions for Scope 2 or Scope 3. This indicates that Medigene's direct emissions from owned or controlled sources are being monitored, while indirect emissions from purchased electricity and other upstream or downstream activities have not been disclosed. Despite the reduction in emissions, Medigene AG has not set specific reduction targets or initiatives, nor are there any commitments to industry-standard climate pledges such as the Science Based Targets initiative (SBTi). The absence of such targets suggests that while the company is actively tracking its emissions, it may not yet be engaging in broader climate commitments or reduction strategies. Overall, Medigene AG's emissions data reflects a focus on direct emissions management, with potential for future climate commitments to enhance its sustainability profile.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

20222023
Scope 1
492,850
000,000
Scope 2
-
-
Scope 3
-
-

How Carbon Intensive is Medigene AG's Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Medigene AG's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is Medigene AG's Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Medigene AG is in DE, which has a medium grid carbon intensity relative to other regions.

Medigene AG's Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

Medigene AG has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare Medigene AG's Emissions with Industry Peers

Astra Zeneca

GB
•
Pharmaceutical Preparation Manufacturing
Updated 9 days ago

Perrigo

IE
•
Pharmaceutical Preparation Manufacturing
Updated 9 days ago

Roche Holding AG

CH
•
Pharmaceutical Preparation Manufacturing
Updated 10 days ago

Merck And Co

US
•
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Gilead Sciences

US
•
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

3M Co., Branded Pharmaceutical Business in North & Latin America

US
Updated 9 days ago

Let us know if this data was useful to you

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251030.3
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy